News of Note—Abbott faces class-action suit over St. Jude defibrillators, and more


Here is Wednesday's medtech news of note.

> St. Jude Medical investors are seeking class-action status in a lawsuit over allegations that the devicemaker—now part of Abbott—did not inform regulators about faulty batteries in its implantable defibrillators. MassDevice article

> Bayer has stopped sales of its Essure birth control implant outside the U.S. for commercial reasons and not safety issues, despite growing concern about the safety of the device. MarketWatch article | FierceMedTech article


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Stryker’s Spine unit notched an FDA nod for its 3D-printed TritaniumC Anterior Cervical Cage. It will launch the device in the fourth quarter. Release

Suggested Articles

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Exact Sciences received an FDA breakthrough designation for its liver cancer blood test as it finalized its $2.8 billion merger with Genomic Health.